SAN DIEGO--(BUSINESS WIRE)--Samumed presented at the 2016 American College of Rheumatology (ACR) Annual Meeting preclinical results from in vitro and in vivo studies regarding the use of its small ...
Samumed, LLC Announces Successful Modulation of the Wnt Pathway for Potential Cartilage Regeneration
SAN FRANCISCO--(BUSINESS WIRE)--At the American College of Rheumatology (ACR) Annual Meeting, Samumed unveiled groundbreaking pre‐clinical and clinical research that demonstrated successful modulation ...
Founded in 2008, Samumed has spent most of its lifetime working under the radar. It came out of the shadows in 2016 with a war chest of $220 million drawn from investors including Ikea’s private ...
Samumed, LLC has raised $438 million, the San Diego regenerative medicine company said Monday. The new financing round brings the total to more than $650 million since Samumed’s founding, valuing the ...
SAN DIEGO, June 01, 2020 (GLOBE NEWSWIRE) -- Samumed, LLC, a clinical-stage biotechnology company pioneering Wnt Pathway therapeutics for major diseases, announced today that Dr. Michael White will ...
SAN DIEGO, May 22, 2020 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today the publication of results from the Phase 2a trial of lorecivivint, an investigational CLK/DYRK1A inhibitor that modulates the ...
SAN DIEGO, April 23, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, a leader in Wnt research and development, today announced it will present its most recent clinical and preclinical data on the company’s ...
San Diego, CA--November 1, 2016 - Samumed, a leader in tissue regeneration, today announced it has been selected to feature seven presentations in five different therapeutic areas at the 2016 American ...
SAN DIEGO--November 6, 2015--Samumed, LLC, a leader in tissue regeneration, announced today that it has started enrolling patients in a Phase II, multicenter, randomized, double-blind, ...
SAN DIEGO, June 19, 2019 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it has dosed the first patient in its Phase 3 STRIDES-X-ray trial of lorecivivint (SM04690), a CLK/DYRK inhibitor that ...
SAN DIEGO and SILVER SPRING, Md., Sept. 17, 2018 /PRNewswire/ -- Samumed LLC has entered an exclusive license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for North American rights to ...
Samumed, LLC, a leader in tissue regeneration, announced today that it will present preclinical and clinical data on a small molecule modulator of the Wnt pathway (SM04690, an investigational new drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results